A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2867

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: CP-690,550
DRUG: CP-690,550

Sponsor

Pfizer